Pharma major, Wanbury's net profit has grown 5.62 times at Rs 9.48 crore in Q1FY10 as against Rs 1.43 crore in the year-ago period.
Its net sales at Rs 83.74 crore in the reporting quarter rose 25.6 per cent as against Rs 66.66 crore in the year-ago period, a press release issued here today said.
EBITDA margin for Q1FY10 was at 19.60 per cent as against 16.40 per cent in Q1FY09.
Wanbury has registered a compounded annual growth rate of 68 per cent over the last 6-years and has a strong presence in domestic formulations, active pharmaceutical ingredients and contract research and manufacturing services (CRAMS), the release said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app